Northwest Biotherapeutics, Inc. has completed its acquisition of Advent BioServices Ltd., making Advent a wholly owned subsidiary. As part of the deal, Northwest Biotherapeutics receives all of Advent's fixed assets, including cryostorage and equipment, as well as intellectual property and other intangibles previously held by Advent. No new shares or securities are being issued; instead, 19 million previously issued securities to Advent, consisting of 13.5 million shares and 5.5 million options, are reverting back to Northwest Biotherapeutics. Payment for the acquisition will be made in installments over two years, with the potential for acceleration following regulatory approval of the DCVax®-L product. The consideration includes £1.4 million and payment of the net accounts payable due for past services, with installment payments scheduled to begin 90 days after the October closing.